Importantly, with high values of tumour/background ratio in PSMA-avid lesions, 18F-DCFPyL PET/CT provides a higher sensitivity than 68 Ga-based tracers for the localization of sites of recurrence, a definite asset for improved management of patients with oligometastatic recurrent prostate cancer (Dietlein et al. 2015; Ceci et al. 2015). This evidence concerns the gene FOLH1 and prostate carcinoma.